Non-toxic biocidal composition

Abstract

The invention refers to compositions comprising: (a) from 20% to 40% by weight of 5-Isopropil-2-metilfenol (carvacrol); (b) from 20% to 38% by weight of 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol); (c) from 21% to 38% by weight of 4-Methyl-1-(propan-2-yl)cyclohex-3-en-1-ol (terpinen-4-ol); and (d) optionally, a further active ingredient, being the sum of ingredients up to 100% by weight. The compositions have a strong biocidal activity and are non-toxic. The invention also refers to products comprising the compositions and uses thereof.

Description

[0001] Non-toxic biocidal composition

[0002] This application claims the benefit of European Patent Application EP24382059.4 filed 24 January 2024.

[0003] The present invention relates to the field of biocide compositions with low toxicity; and products comprising it.

[0004] Background Art

[0005] Currently, bactericidal, virucidal, fungicidal, and yeasticidal agents used in the field of disinfection are of industrial chemical origin. Said agents comprise quaternary ammonium salts, ethanol and other elements that can be harmful to the environment, since in high proportions they are hardly biodegradable. In addition, their prolonged use can generate resistance that reduces its effectiveness. For these reasons, alternative antimicrobial and virucidal agents of natural origin have been developed including carbohydrates, alcohols, esters, aldehydes, and ketones. These essential oils are responsible for the biological properties of aromatic and medicinal plants. Several essential oils and their components also have pharmacological effects due to their proven anti-inflammatory, antioxidant, and anticancer properties. However, the extraction of these essential oils involves a very high cost, since very large amounts of raw material are needed, and they have a very significant negative impact on the ecosystem from which they are obtained.

[0006] Although the antimicrobial and viricidal effect of some of the active ingredients of said essential oils has been previously demonstrated, the minimum amount of said active ingredients that are necessary to ensure an inhibitory activity, that is, what is known as minimum inhibitory concentration (MIC), are too high (Halldor Thormar, Lipids and Essential Oils as Antimicrobial Agents, Wiley Ed). It implies that the effective biocidal amount of these active ingredients is very high, and it has a direct and unaffordable impact in the cost of production of antimicrobial products that include them, in addition to the already mentioned negative effect on the environment. Furthermore, the higher the necessary dosage amount of these active ingredients, the greater the possibility of occurring adverse reactions to them.

[0007] Therefore, there is still the need to provide effective, stable, and cheap compositions having an immediate and prolonged broad-spectrum biocidal activity and low toxicity.

[0008] Summary of the invention

[0009] The present inventors have carried out extensive research to arrive at the optimal combination of active ingredients that work synergically while maintaining a low toxicity profile, thereby overcoming the abovementioned problems. Said biocidal composition comprises 5-isopropil-2-metilfenol, 1 ,3,3-trimethyl-2- oxabicyclo[2.2.2]octane, and 4-methyl-1-(propan-2-yl)cyclohex-3-en-1-ol, optionally together with a further ingredient.

[0010] The composition of the present invention has an enhanced and broad-spectrum biocidal activity. As it is demonstrated in the experimental section, the composition of the present invention has an unexpectedly effective activity as bactericidal, fungicidal, virucidal and yeasticidal, even when very low concentrations are used. In fact, this enhanced effect is much higher than the sum of biocide effect of each one of the active ingredients separately (as it is demonstrated in the examples below). Therefore, the composition of the present invention shows a synergistic biocide effect even at much lower concentrations than the ingredients separately. As it is demonstrated in the experimental section, this enhanced effect is shown in the treatment or prevention of infected surfaces; and also for the treatment or prevention of space / environment for a domestic use or a professional activity. In fact, the effectivity of the compositions of the invention is higher and prolonged in time than the effectivity shown for bleach. Furthermore, the unexpected synergic effect between the ingredients makes it possible to reduce the concentration required for each compound in the combination, thus greatly reducing toxicity and environmental hazards.

[0011] The composition of the present invention is also advantageous because is versatile being useful in the manufacturing of products for several fields such as pharmacy, veterinary, cosmetic, agro- or phytosanitary field, hygiene / cleaning industry and perfumery fields. In fact, the composition of also useful in the food / feed industry for human / animal consumption since all active ingredients of the composition of the invention can be of "food / feed grade”. Also, because it may be used at such a low concentration, it does not alter the formulations of cosmetic products or generate any type of adverse effect (irritation, allergies, etc.) on the skin.

[0012] Furthermore, the compositions of the present invention are stable under manufacturing, storage, and normal use conditions; and can be used in low amounts without compromising the biocidal activity, such that, for example, a biocidal efficacy of up to 98.7% is maintained in 10 days from the first application of the product. In fact, they have a long half-life reducing the number of applications (spacing the use) without hindering the biocidal effect. It implies that the cost of its use is considerable reduced, and that the useful life of the surface or object to be treated is increasing. It is specially advantageous when the composition is used in cosmetic, food / feed industry and perfumery fields because it allows simplifying the procedure protocols spacing the frequency of application without compromising the quality and lowering the economic cost. Besides, biocidal efficacy of the compositions is maintained throughout a broad pH range and it achieves surprisingly good disinfection even when applied by fogging.

[0013] The composition of the invention may be used by itself or in combination with a further biocidal active ingredient. Indeed, the composition of the present invention also shows an unexpected synergic effect when combined with other biocidal active ingredient. This effect is commonly known as biocidal booster effect. Without being bound to any theory, this effect can be associated to the fact that the composition of the invention is also useful for inhibiting the adherence of the pathogens to the surface since inhibits the growth of biofilm. It means that apart from its inherent capacity of killing pathogens, the composition of the invention is also useful as adjuvant to other biocide active ingredients and as a biocide booster. The composition of the present invention is effective against the most common pathogens (including bacteria, fungi, and yeast) that cause a higher incidence of disease in human and animals. This high effectivity and broad spectrum is achieved even of using a low effective amount of the composition. Besides, the composition of the present invention is also effective against pathogens that have resistance to antibiotics (mainly because the spore formation capability-such as C. difficile) and new pathogens (SARS-Cov-2). As demonstrated in the examples below, the composition is also effective against biofilms formed by pathogenic microorganisms such as Pseudomonas aeruginosa or Acinetobacter Baumannii, thus being particularly useful is hospital environments where such biofilms and resistant pathogens are of great concern.

[0014] Finally, the compositions of the present invention have a very small impact on the environment and their use does not generate adverse effects on the ecosystem from which they are obtained or on living beings. The combinations further do not require rinsing after application for disinfection processes.

[0015] Thus, the first aspect of the invention relates to a composition comprising:

[0016] (a) from 20% to 40% by weight of 5-lsopropil-2-metilfenol (carvacrol);

[0017] (b) from 20% to 38% by weight of 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol);

[0018] (c) from 21% to 38% by weight of 4-Methyl-1-(propan-2-yl)cyclohex-3-en-1-ol (terpinen-4-ol);

[0019] (d) optionally, a further active ingredient selected from the group consisting of Tartaric acid, (9Z, 12E)- tetradeca-9, 12-dien-1 -yl acetate, Acetic acid, Arnica montana extract, Ascorbic acid, Bentonite, Carbon dioxide, Citronella, D-Fructose, Honey, Iron, Iron sulphate, Lavender oil, Linseed oil, Nitrogen, Oct-1 -en-3-ol, Peppermint oil, Potassium Sorbate, Propionic acid, Saccharomyces cerevisiae, Silicic acid or an aluminium, magnesium, or sodium salt thereof, Sodium acetate, Sodium benzoate, trisodium orthophosphate, acetic acid, lactic acid, citric acid, and combinations thereof; and

[0020] (e) optionally, a further active ingredient selected from the group consisting of Calcium carbonate, potassium bicarbonate, methylcyclopropene, ABE-IT 56, Mancozeb, Azoxystrobin, Tebuconazole, Chlorothalonil, Propiconazole, Oxamyl, Metam sodium, 1 ,3-Dichloropropene, Fluensulfone, Phosthiazate, Oxytetracycline, Streptomycin, Copper oxychloride, Kasugamycin, Chloropicrin, Phosphorous acid, Phosphoric acid, methyl bromide, N-Trichloromethylthio-4-cyclohexene-1,2-dicarboximide, Fluor, Copper Hydroxide, a silver salt (such as silver nitrate, Silver sulfadiazine, Silver sulfate, Silver acetate, Silver oxide, Silver phosphate, or Silver thiosulfate), Silver nanoparticles, a Copper salt (such as Copper sulfate, Copper oxychloride, Copper hydroxide, or Dicopper trihydroxychloride), Cymoxanil, Metalaxyl, Folpet, Baculovirus, chabazite, cheese, concentrated apple juice, webbing clothes moths pheromone, Wolbachia pipientis strain wPip, vinegar, and combinations thereof, being the sum of ingredients up to 100% by weight.

[0021] The second aspect of the invention relates to a product comprising: (I) an effective amount of a composition as defined in the first aspect of the invention; and (ii) one or more appropriate acceptable excipients of carriers. The third aspect of the invention is the use of the composition of the first aspect of the invention or the product of the second aspect of the invention in therapy (pharmacy and veterinary), cosmetic, agriculture, food / feed / dietetic industry, hygiene / cleaning industry, and scented / perfumery industry.

[0022] It is also part of the invention processes for the preparation of the compositions of the first aspect of the invention and the products comprising them of the second aspect of the invention.

[0023] Detailed description of the invention

[0024] All terms as used herein in this application, unless otherwise stated, shall be understood in their ordinary meaning as known in the art. Other more specific definitions for certain terms as used in the present application are as set forth below and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition.

[0025] For the purposes of the present invention, any ranges given include both the lower and the upper end-points of the range. Ranges given, such as weight, temperatures, times, weights, and the like, should be considered approximate, unless specifically stated.

[0026] The terms "percentage (%) by weight”, "weight / weight %” and “w / w%” have the same meaning and are used interchangeable. They refer to the percentage of each ingredient of the composition in relation to the total weight of the composition. For example, 1% by weight corresponds to 1 g in 100 g of total weight).

[0027] The term "extract” refers to the conventional sense to refer to concentrated preparations of plants obtained by removing the active constituents from the plant with suitable means. Such actives constituents can be obtained from various parts of the plant using different extraction / distill ation techniques. Suitable means for removal of the active ingredients include, for example, use of steam entrainment, CO2, supercritical fluids, hydro distillation, microwaves, organic solvents depending on the plant of origin and the active ingredient / s it contains, being able to be performed in cold temperatures or any specific temperatures in each process for the adequate extraction. Active ingredients thus obtained are sometimes directly incorporated in food / feed, pharmaceutical or cosmetic compositions in a variety of forms, including a pure or semi-pure component, a solid or liquid extract, or a solid algae matter. Plant extracts contain not only one but multiple constituents, many of them active. Extracts comprising the active ingredients of the present invention (for example carvacrol, eucalyptol, terpinen-4-ol, as well as, if present, thymol and / or menthol) may be obtained from plan extracts, for example, selected from the group consisting of Myrtaceae family extract (for instance genus eucalyptus extract such as Eucalyptus globulus; genus Melaleuca such as Melaleuca altemifolia)', Lamiaceae family extract (for instance genus Mentha such as Mentha piperita; genus Thymus such as Thymus zygis, Thymus vulgaris, and Thymus capitata; and genus Origanum such as Origanum vulgare), Rutacea family extract (for instance genus Citrus extract such as Citrus reticulata), Cupressaceae family extract (for instance genus Juniperus such as Juniperus oxycedrus); and Pinaceae family extract (for instance genus Pinus such as Pinus sylvestris); and mixtures thereof. For the purpose of the invention the claimed amount corresponds to the pure active ingredients or such amount of extract that included the claimed amount of the pure active ingredient. For the purpose of the invention, the term "essential oil” refers to an extract which has been highly concentrated and purified. Therefore, the term "extract” encompasses "essential oils”. For the present invention, the active ingredients are preferably isolated or obtained by synthesis and used in "pure” form. The present ingredients are commercially available in pure form from several providers.

[0028] Compositions

[0029] As it is mentioned above, the composition of the first aspect of the invention comprises: 5-lsopropi 1-2- metilfenol (carvacrol); 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol); 4-Methyl-1-(propan-2- yl)cyclohex-3-en-1-ol (terpinen-4-ol); and optionally, a further active ingredient.

[0030] In the context of the invention, the compound “5-lsopropil-2-metilfenol” and "carvacrol” have the same meaning and are used interchangeable. They refers to the compound having the CAS number 499-75-2 and the following structure:

[0031] The composition of the invention comprises from 0.1% to 40% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 0.5% to 40% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 1% to 40% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 2% to 40% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 3% to 40% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 3.5% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 4% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 8% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 15% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 25% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 30% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 10% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 20% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 28% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises from 31% to 34% by weight of carvacrol. In an embodiment, the composition of the invention comprises 33% by weight of carvacrol.

[0032] In the context of the invention, the compound “1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane”, "1 ,8-cineole”, and "eucalyptol” have the same meaning and are used interchangeable. They refer to the compound having the CAS number 470-82-6 and the following structure:

[0033] The composition of the invention comprises from 0.1% to 40% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 0.5% to 40% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 1% to 40% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 2% to 40% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 5% to 40% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 10% to 38% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 15% to 38% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 20% to 38% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 5% to 34% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 10% to 34% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 15% to 34% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 20% to 34% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 25% to 34% by weight of eucalyptol. In an embodiment, the composition of the invention comprises from 30% to 34% by weight of eucalyptol. In an embodiment, the composition of the invention comprises 33% by weight of eucalyptol.

[0034] In the context of the invention, the compound (c) "4-Methyl-1-(propan-2-yl)cyclohex-3-en-1-ol” and "terpinen- 4-ol” have the same meaning and are used interchangeable. They refers to the compound having the following structure:

[0035] For the purpose of the present invention the term terpinen-4-ol encompasses both the enantiomers separately (i.e. R-enantiomer and S-enantiomer) and an "enantiomeric mixture" containing them. The term "enantiomeric mixture" as used herein refers to a mixture of the two enantiomers including the racemic mixture and any mixture enriched in one of the two enantiomers. The term "racemic mixture" or "racemate” as used herein refers to a mixture of both enantiomers which comprises equal amounts of the R-enantiomer and the S- enantiomer, which means that the molar ratio of the two enantiomers in the racemic mixture is 50:50. The term "mixture enriched in one enantiomer” as used herein refers to a mixture of enantiomers (R-enantiomer and S-enantiomer), which comprises a higher amount of one enantiomer with respect to the other enantiomer respectively, which means that the molar ratio of the two enantiomers in the enantiomerical ly enriched mixture is other than 50:50.

[0036] The term "enantiomeric excess" (ee) refers to the difference between the amounts of each of the enantiomers present in a mixture, relative to the total amount of the compound in the mixture expressed as percentage (x 100%). For an excess of the R-enantiomer, the enantiomeric excess can be calculated by the following formula: ee % = ([R] - [S]) I ([R] + [S]) x100

[0037] For an excess of the S-enantiomer, the enantiomeric excess can be calculated by the following formula: ee % = ([S] - [R]) I ([R] + [S]) x100

[0038] The term "enantiomeric purity" (ep) refers to the purity of an enantiomer with respect to the other enantiomer.

[0039] For an excess of the R-enantiomer, the enantiomeric purity can be calculated by the following formula: ep % = ([R] I ([R] + [S]) x100

[0040] For an excess of the S-enantiomer, the enantiomeric purity can be calculated by the following formula: ep % = ([S] I ([R] + [S]) x100

[0041] In the above formulas, [R] and [S] are the respective molar fractions of the enantiomers in a mixture such that [R] + [S] = 1.

[0042] For the purpose of the present invention, the racemic mixture of the terpinene-4-ol refers to the compound of CAS number 562-74-3 having the following structure:

[0043] The (S)-enantiomer of the terpinene-4-ol refers to the compound of CAS number 2438-10-0 having the following structure:

[0044] The (R)-enantiomer of the terpinene-4-ol refers to the compound of CAS number 20126-76-5 having the following structure.

[0045] The composition of the invention comprises from 0.1% to 40% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 5% to 40% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 10% to 38% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 15% to 38% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 20% to 38% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 25% to 38% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 30% to 38% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 5% to 34% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 10% to 34% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 15% to 34% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 20% to 34% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 25% to 34% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 28% to 34% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises from 30% to 34% by weight of terpinen-4-ol. In an embodiment, the composition of the invention comprises 33% by weight of terpinen-4-ol.

[0046] The % by weigh ratio of carvacrol, eucalyptol, and terpinen-4-ol (herein expressed as %carvacrol:%eucalyptol:%terpinen-4-ol or, simply, carvacrol:eucalyptol:terpinen-4-ol) may be 0.5-1.5:0.5- 1 .5:0.5-1 .5. In one embodiment the ratio is 0.8-1 .2:0.8-1 .2-0.8- 1.2. In a particular embodiment the ratio is 0.9- 1.1 :0.9-1.1 :0.9-1.1), for example, the ratio may be 1 :1 :1.

[0047] In a particular embodiment, the composition of the invention comprises from 25 to 34% by weight of carvacrol, 25 to 34% by weight of eucalyptol, and 25 to 34% by weight of terpinen-4-ol. In a very particular embodiment, the composition of the invention comprises from 28 to 34% by weight of carvacrol, 28 to 34% by weight of eucalyptol, and 28 to 34% by weight of terpinen-4-ol. In a preferred embodiment, the composition of the invention comprises from 30 to 34% by weight of carvacrol, 30 to 34% by weight of eucalyptol, and 30 to 34% by weight of terpinen-4-ol. In a preferred example, the composition comprises 33% by weight of carvacrol, 33% by weight of eucalyptol, and 33% by weight of terpinen-4-ol. These compositions provide an outstanding biocidal effect while maintaining a very low toxicity compatible with existing standards, such that, for example, the products of the invention may be registered as non-hazardous and non-toxic biocide products according to ECHA regulations (https: / / echa.europa.eu / es / regulations / biocidal-products-regulation / authorisation-of- biocidal-products / simplified-authorisation). This is achieved thanks to the synergy that has been found among these components, and could not be achieved with any of the individual components.

[0048] These compositions may optionally contain a further active ingredient. In one embodiment, the further active ingredient is selected from the group consisting of Tartaric acid (CAS: 87-69-4), (9Z, 12E)-tetradeca-9, 12-dien- 1-yl acetate (CAS: 30507-70-1), Acetic acid (CAS: 64-19-7), Arnica montana extract (CAS: 68990-11-4), Ascorbic acid (CAS: 50-81-7) , Bentonite (CAS: 1302-78-9), Carbon dioxide (CAS: 124-38-9), Citronella (CAS: 106-23-0), D-Fructose (CAS: 57-48-7), Honey (CAS: 8082-66-8), Iron (CAS: 7439-89-6), Iron sulphate (CAS: 7720-78-7) , Lavender oil (CAS: 8000-28-0), Linseed oil (CAS: 8001-26-1) , Nitrogen (CAS: 7727-37-9), Oct-

[0049] I-en-3-ol (CAS: 3391-86-4), Peppermint oil (CAS: 8006-90-4) , Potassium Sorbate (CAS: 24634-61-5), Propionic acid (CAS: 79-09-4), Saccharomyces cerevisiae (CAS: 68876-77-7), Silicic acid or an aluminium, magnesium, or sodium salt thereof (CAS: 68876-77-7), Sodium acetate (CAS: 127-09-3), Sodium benzoate (CAS: 523-32-1), trisodium orthophosphate (CAS: 7601-54-9), acetic acid (CAS: 64-19-7), lactic acid (CAS: 50-21-5), citric acid (CAS: 77-92-9), and combinations thereof. In particular embodiments, the preferred compositions mentioned above contain said further active ingredient. In one embodiment, the further active ingredient may be selected from the group consisting of Tartaric acid (CAS: 201-766-0), (9Z,12E)-tetradeca- 9, 12-dien-1-yl acetate (CAS: 30507-70-1), Acetic acid (CAS: 64-19-7), Arnica montana extract (CAS: 68990-

[0050] I I-4), Ascorbic acid (50-81-7), Bentonite (CAS: 1302-78-9), Carbon dioxide (CAS: 124-38-9), Citronella (CAS: 106-23-0), D-Fructose (CAS: 57-48-7), Honey (CAS: 8082-66-8), Iron (CAS: 7439-89-6), Iron sulphate (CAS: 7720-78-7), Lavender oil (CAS: 8000-28-0), Linseed oil (CAS: 8001-26-1), Nitrogen (CAS: 7727-37-9), Oct-1- en-3-ol (CAS: 3391-86-4), Peppermint oil (CAS: 8006-90-4), Potassium Sorbate (CAS: 24634-61-5), Propionic acid (CAS: 79-09-4), Saccharomyces cerevisiae (CAS: 68876-77-7), Silicic acid or an aluminium, magnesium, or sodium salt thereof (CAS: 68876-77-7), Sodium acetate (CAS: 127-09-3), Sodium benzoate (CAS: 523-32- 1), trisodium orthophosphate (CAS: 7601-54-9), acetic acid (CAS: 64-19-7), and combinations thereof. In a particular embodiment the further active ingredient is selected from the group consisting of Sodium benzoate (CAS: 523-32-1), Sodium acetate (CAS: 127-09-3), Peppermint oil (CAS: 8006-90-4), Citronella (CAS: 106- 23-0), acetic acid (CAS: 64-19-7), Iron sulphate (CAS: 7720-78-7), Tartaric acid (CAS: 87-69-4), Propionic acid (CAS: 79-09-4), trisodium orthophosphate (CAS: 7601-54-9), Lavender oil (CAS: 8000-28-0), and combinations thereof. In another embodiment, the further active ingredient is selected from the group consisting of tartaric acid (CAS: 87-69-4), lactic acid (CAS: 50-21-5), citric acid (CAS: 77-92-9), Peppermint oil (CAS: 8006-90-4), Benzoic acid (CAS: 65-85-0), and combinations thereof. In another embodiment the further active ingredient is selected from the group consisting of Calcium carbonate (CAS: 471-34-1), potassium bicarbonate (CAS: 298-14-6), methylcyclopropene (CAS: 3100-04-7), ABE-IT 56 (a component from Saccharomyces cerevisiae strain DDSF623, doi: 10.2903 / j.efsa.2018.5400), Mancozeb (CAS: 8018-01-7), Azoxystrobin (CAS: 131860-33-8), Tebuconazole (CAS: 107534-96-3), Chlorothalonil (CAS: 1897-45-6), Propiconazole (CAS: 60207-90-1), Oxamyl (CAS: 23135-22-0), Metam sodium (CAS: 137-42-8), 1,3- Dichloropropene (CAS: 542-75-6), Fluensulfone (CAS: 318290-98-1), Phosthiazate (CAS: 98886-44-3), Oxytetracycline (CAS: 79-57-2), Streptomycin (CAS: 57-92-1), Copper oxychloride (CAS: 1332-40-7), Kasugamycin (CAS: 6980-18-3), Chloropicrin (CAS: 76-06-2), Phosphorous acid (CAS: 13598-36-2) .Phosphoric acid (CAS: 7664-38-2) methyl bromide (CAS: 74-83-9), N-Trichloromethylthio-4-cyclohexene-1 ,2- dicarboximide (CAS: 133-06-2), Fluor (CAS: 7782-41-4), Copper Hydroxide (CAS: 20427-59-2), a silver salt (such as silver nitrate (CAS: 7761-88-8), Silver sulfadiazine (CAS: 22199-08-2), Silver sulfate (CAS: 10294- 26-5), Silver acetate (CAS: 563-63-3), Silver oxide (CAS: 20667-12-3), Silver phosphate (CAS: 13465-97-9), or Silver thiosulfate (CAS: 10294-26-5)), Silver nanoparticles (for example those with CAS: 7440-22-4), a Copper salt (such as Copper sulfate (CAS: 7758-98-7), Copper oxychloride (CAS: 1332-65-6-6), Copper hydroxide (CAS: 20427-59-2), or Dicopper trihydroxychloride (CAS: 1332-40-7)), Cymoxanil (CAS: 57966-95- 7), Metalaxyl (CAS: 57837-19-1), Folpet (CAS: 133-07-3), Baculovirus, chabazite, cheese, concentrated apple juice, webbing clothes moths pheromone, Wolbachia pipientis strain wPip, vinegar (CAS: 8028-52-2), and combinations thereof. Some of these further active ingredients have some type of biocidal activity. The biocidal activity of the further active ingredients is boosted when used in combination with the composition of the invention comprising carvacrol, eucalyptol, and terpinen-4-ol.

[0051] The further active ingredient as defined above may be comprised in the composition in a concentration from 0.01 to 10% by weight. In some embodiments, the concentration of the further active ingredient as defined above is from 0.01 to 1%, or from 0.05 to 1%, or from 0.1 to 1%. For example, the active ingredients Tartaric acid, (9Z,12E)-tetradeca-9,12-dien-1-yl acetate, Acetic acid, Citronella, Iron sulphate, Lavender oil, Oct-1-en- 3-ol, Peppermint oil, Potassium Sorbate, Propionic acid, Sodium benzoate, trisodium orthophosphate, lactic acid, citric acid are preferably used at concentrations from 0.01 to 1% In another example, the active ingredients Arnica montana extract, Ascorbic acid, Bentonite, Carbon dioxide, D-Fructose, Honey, Iron, Linseed oil, Nitrogen, Saccharomyces cerevisiae, Silicic acid or an aluminium magnesium, or sodium salt, Sodium acetate are preferably used at concentrations from 0.01 to 10%.

[0052] The composition of the invention may also contain thymol and / or menthol. In the context of the invention, the compound (c) "5-Methy l-2-(propan-2-y l)phenol” and "thymol” have the same meaning and are used interchangeable. They refers to the compound having the CAS number 89-83-8 and the following structure: The composition of the invention comprises from 0.1% to 30% by weight of thymol. In an embodiment, the composition of the invention comprises from 1% to 30% by weight of thymol. In an embodiment, the composition of the invention comprises from 5% to 30% by weight of thymol. In an embodiment, the composition of the invention comprises from 10% to 30% by weight of thymol. In an embodiment, the composition of the invention comprises from 15% to 30% by weight of thymol. In an embodiment, the composition of the invention comprises from 20% to 30% by weight of thymol. In an embodiment, the composition of the invention comprises from 23% to 30% by weight of thymol. In an embodiment, the composition of the invention comprises from 1% to 26% by weight of thymol. In an embodiment, the composition of the invention comprises from 5% to 26% by weight of thymol. In an embodiment, the composition of the invention comprises from 10% to 26% by weight of thymol. In an embodiment, the composition of the invention comprises from 15% to 26% by weight of thymol. In an embodiment, the composition of the invention comprises from 20% to 26% by weight of thymol. In an embodiment, the composition of the invention comprises from 24% to 26% by weight of thymol. In an embodiment, the composition of the invention comprises 25% by weight of thymol.

[0053] In the context of the invention, the compound (c) "5-Methyl-2-(propan-2-yl)cyclohexan-1-ol” and "menthol” have the same meaning and are used interchangeable. They refers to the compound having the CAS number 89-78-1 and the following structure:

[0054] For the purpose of the present invention the term 5-Methyl-2-(propan-2-yl)cyclohexan-1-ol encompasses all possible isomers separately and also "isomeric mixtures" containing them including the racemic mixture.

[0055] One of the isomers of the 5-Methyl-2-(propan-2-yl)cyclohexan-1-ol is the compound having the CAS number 2216-51-5 and the following structure:

[0056] The composition of the invention comprises from 0.1% to 30% by weight of menthol. In an embodiment, the composition of the invention comprises from 1% to 30% by weight of menthol. In an embodiment, the composition of the invention comprises from 5% to 30% by weight of menthol. In an embodiment, the composition of the invention comprises from 10% to 30% by weight of menthol. In an embodiment, the composition of the invention comprises from 15% to 30% by weight of menthol. In an embodiment, the composition of the invention comprises from 20% to 30% by weight of menthol. In an embodiment, the composition of the invention comprises from 23% to 30% by weight of menthol. In an embodiment, the composition of the invention comprises from 1% to 26% by weight of menthol. In an embodiment, the composition of the invention comprises from 5% to 26% by weight of menthol. In an embodiment, the composition of the invention comprises from 10% to 26% by weight of menthol. In an embodiment, the composition of the invention comprises from 15% to 26% by weight of menthol. In an embodiment, the composition of the invention comprises from 20% to 26% by weight of menthol. In an embodiment, the composition of the invention comprises from 23% to 26% by weight of menthol. In an embodiment, the composition of the invention comprises 20% by weight of menthol.

[0057] The composition of the invention comprises carvacrol, eucalyptol and terpinen-4-ol. In one embodiment, the composition consists essentially of carvacrol, eucalyptol and terpinen-4-ol. In an embodiment, the composition comprises carvacrol, eucalyptol, terpinen-4-ol, and thymol. In an embodiment, the composition consists essentially of carvacrol, eucalyptol, terpinen-4-ol, and thymol. In an embodiment, the composition comprises carvacrol, eucalyptol, terpinen-4-ol, thymol, and menthol. In any of these embodiments the composition may additionally comprise a further active ingredient as defined above. In an embodiment, the composition consists essentially of carvacrol, eucalyptol, terpinen-4-ol, menthol, and thymol. In the sense of the present invention the expression "consisting essentially of' means that specific further components can be present, namely those not materially affecting the essential characteristics of the composition. The present invention also contemplates compositions as disclosed in the embodiments above or below, wherein the consisting essentially of is replaced by consisting of.

[0058] The ingredients can be provided from extracts containing them or included as pure or substantially pure substances, either isolated from an extract containing them or prepared synthetically. In all the embodiments above or below, the active ingredients are preferably included as pure ingredients (not as extracts comprising them). Using the pure ingredients has the advantage that the concentration of active ingredients in the composition may be tightly controlled, which is important to obtain the desired combination of active ingredients and to avoid other substances or contaminants which provide un-desired complexity or toxicity. In this sense, it is noted that extracts are often obtained using solvents that may be considered toxic.

[0059] In particular embodiments, the composition comprises or consists essentially of: from 20% to 40% by weight of carvacrol; from 20% to 38% by weight of eucalyptol; and from 21 % to 38% by weight of terpinen-4-ol; being the sum of ingredients up to 100% by weight. In these particular embodiment, the composition may further comprise or consist essentially of from 0.01 to 10% of a further active ingredient as defined above. In particular embodiments, the composition further comprises or consists essentially of from 15% to 30% by weight of thymol. In other particular embodiments, the composition further comprises or consists essentially of from 15% to 30% by weight of menthol. In some embodiments, the composition further comprises or consists essentially of one or more additional active ingredients (different from the further active ingredient defined above) and / or one or more appropriate acceptable excipients or carriers. The sum of ingredients is always up to 100% by weight.

[0060] In a more particular embodiment, the composition comprises or consists essentially of: from 20% to 30% by weight of carvacrol; from 20% to 30% by weight of eucalyptol; from 21 % to 30% by weight of terpinen-4-ol; and 20% to 30% by weight of thymol, being the sum of ingredients up to 100% by weight. In this particular embodiment, the composition may further comprise or consist essentially of from 0.01 to 10% of a further active ingredient as defined above. In some embodiments, the composition further comprises or consists essentially of one or more additional active ingredients (different from the further active ingredient defined above) and / or one or more appropriate acceptable excipients or carriers. This composition may further comprise or consist essentially of menthol. The sum of ingredients is always up to 100% by weight.

[0061] In a more particular embodiment, the composition comprises or consists essentially of: from 23% to 26% by weight of carvacrol; from 23% to 26% by weight of eucalyptol; from 23% to 26% by weight of terpinen-4-ol; and 23% to 26% by weight of thymol, being the sum of ingredients up to 100% by weight. In these particular embodiments, the composition may further comprise or consist essentially of from 0.01 to 10% of a further active ingredient as defined above. In some embodiments, the composition further comprises or consists essentially of one or more additional active ingredients (different from the further active ingredient defined above) and / or one or more appropriate acceptable excipients or carriers. This composition may further comprise or consist essentially of menthol. The sum of ingredients is always up to 100% by weight.

[0062] In a more particular embodiment, the composition comprises or consists essentially of around: 25% by weight of carvacrol; 25% by weight of eucalyptol; 25% by weight of terpinen-4-ol; and 25% by weight of thymol being the sum of ingredients up to 100% by weight. In this particular embodiment, the composition may further comprise or consist essentially of from 0.01 to 10% of a further active ingredient as defined above. In some embodiments, the composition further comprises or consists essentially of one or more additional active ingredients (different from the further active ingredient defined above) and / or one or more appropriate acceptable excipients or carriers. In other particular embodiments, the composition further comprises or consists essentially of menthol. The sum of ingredients is always up to 100% by weight.

[0063] In a more particular embodiment, the composition comprises or consists essentially of: from 15 to 25% by weight of carvacrol; from 15 to 25 % by weight of eucalyptol; from 15 to 25 % by weight of terpinen-4-ol; from 15% to 25% by weight of thymol; and from 15% to 25% by weight of menthol. In another more particular embodiment, the composition comprises or consists of carvacrol from 18 to 23 % by weight; eucalyptol from 18 to 23 % by weight; terpinen-4-ol from 18 to 23 % by weight; menthol from 18 to 23 % by weight; and thymol from 18 to 23 % by weight. In another more particular embodiment, the composition comprises or consists of: 20 % by weight carvacrol; 20 % by weight eucalyptol; 20 % by weight terpinen-4-ol; 20 % by weight thymol; and 20 % by weight menthol. In any of these embodiments, the composition may further comprise or consist essentially of from 0.01 to 10% of a further active ingredient as defined above. In some embodiments, the composition further comprises or consists essentially of one or more additional active ingredients (different from the further active ingredient defined above) and / or one or more appropriate acceptable excipients or carriers. The sum of ingredients is always up to 100% by weight.

[0064] In particular embodiments, the compositions disclosed in the embodiments above consist essentially of carvacrol, eucalyptol and terpinene-4-ol. In other particular embodiments the compositions disclosed in the embodiments above consist essentially of carvacrol, eucalyptol, terpinene-4-ol and a further active ingredient as defined above. In other particular embodiments the compositions disclosed in the embodiments above consist essentially of carvacrol, eucalyptol, terpinene-4-ol and thymol. In other particular embodiments the compositions disclosed in the embodiments above consist essentially of carvacrol, eucalyptol, terpinene-4-ol, thymol and methol. In other particular embodiments the compositions disclosed in the embodiments above consist essentially of carvacrol, eucalyptol, terpinene-4-ol, a further active ingredient as defined above, and one or more appropriate acceptable excipients or carriers . In preferred embodiments the compositions disclosed in the embodiments above comprise carvacrol, eucalyptol, terpinene-4-ol and optionally thymol and / or methol as sole active ingredients, preferably as pure ingredients.

[0065] In an embodiment, the composition is one as disclosed herein below and above which has a pH equal to or lower than 8. In an embodiment, the composition is one as disclosed herein below and above which has a pH equal to or lower than 7.5. In an embodiment, the composition is one as disclosed herein below and above which has a pH equal to or lower than 7. These compositions are specially advantageous for the treatment or prevention of pathogen infection on living surfaces, for instance skin, scalp, and soft tissues.

[0066] In an embodiment, the composition is one as disclosed herein below and above which has a pH higher than 8. In an embodiment, the composition is one as disclosed herein below and above which has a pH higher than 9. These compositions are specially advantageous for the treatment or prevention of pathogen infection on inanimate surfaces and for water and air treatment / prevention.

[0067] In an embodiment, the composition of the invention further comprises one or more additional active ingredients (different from the further active ingredient defined above, i.e. one of those selected from the group consisting of Tartaric acid, (9Z,12E)-tetradeca-9,12-dien-1-yl acetate, Acetic acid, Arnica montana extract, Ascorbic acid, Bentonite, Carbon dioxide, Citronella, D-Fructose, Honey, Iron, Iron sulphate, Lavender oil, Linseed oil, Nitrogen, Oct-1-en-3-ol, Peppermint oil, Potassium Sorbate, Propionic acid, Saccharomyces cerevisiae, Silicic acid or an aluminium, magnesium, or sodium salt thereof, Sodium acetate, Sodium benzoate, trisodium orthophosphate, acetic acid, lactic acid, citric acid, and combinations thereof). In an embodiment, the composition of the invention further comprises one or more additional active ingredients selected from the group consisting of antibiotic, viricide, fungicide, yeasticide, bactericide, skin conditioner, and prebiotic. In an embodiment, the one or more additional active ingredients are selected from the group consisting of organic acid containing compound; quaternary ammonium containing compound, such as quaternary ammonium silane salt; methyl n-methyl anthranilate; guaiacol; p-cresol, cinnamaldehyde, geraniol, citral, methyl dihydrojasmonate (Hedione), 3-(3-propan-2-ylphenyl)butanal (florhydral), cis-para-menthanol (Cyclohexane methanol, 4-(1 -methylethyl)-, cis-), delta-damascone, eugenol, p-cymene, alfa-pinene, betapinene, beta-caryophyllene, caryophylene oxyde, terpinene, and terpinolene. In particular, the one or more additional active ingredients are selected from the group consisting of lactic acid, citric acid, hyaluronic acid, pyruvic acid, ferulic acid, benzalkonium chloride, dimethyl octadecyl[3-(trimethoxy silyl)propyl] ammonium chloride, methyl n-methyl anthranilate; guaiacol; p-cresol, cinnamaldehyde, geraniol, and citral.

[0068] In an embodiment, the composition of the invention further comprises one or more quaternary ammonium containing compound; particularly selected from the group consisting of benzalkonium chloride, dimethyl octadecyl[3-(trimethoxy silyl)propyl] ammonium chloride, and mixture thereof; particularly from 0.01 to 50% by weight; and more particularly from 5 to 20% by weight. In an embodiment, the composition of the invention further comprises a mixture of methyl n-methyl anthranilate; guaiacol; and p-cresol; as additional active ingredients; particularly, from 0.1% to 25% by weight of methyl n-methyl anthranilate; from 0.1% to 25% by weight of guaiacol; and from 0.1% to 25% by weight of p-cresol. In an embodiment, the composition of the invention further comprises one or more additional active ingredients selected from the group consisting of cinnamaldehyde, geraniol, and citral; particularly from 5% to 20% by weight.

[0069] All the embodiments mentioned above for the compositions of the present invention comprising carvacrol, eucalyptol, terpinene-4-ol, and optionally thymol and / or menthol; also apply herein with the addition of one or more additional active ingredients mentioned above.

[0070] In an embodiment, one or more of the active ingredients of the compositions of the present invention can be in free form or alternatively in particulate form. In an embodiment, one or more of the active ingredients of the compositions of the present invention are in particulate form separately or in combination thereof selected from the group consisting of capsules (such as microcapsules or nanocapsules), and liposomes, micelles.

[0071] As mentioned above, the composition of the invention may further comprise one or more appropriate acceptable excipients or carriers. The appropriate excipients and / or carriers, and their amounts, can readily be determined by those skilled in the art according to the type of formulation being prepared and its application. In an embodiment, the one or more appropriate acceptable excipients or carriers are selected from the group consisting of humectant, surfactants, pH-regulating, gelling agent, solvents, co-solvents, rheological modifier agent, preservative, antioxidants, emulsifying agent, stabilizer, chelating agent, flavouring agent, masking, opacifier, binding agent, emollient, sweetener, fragrance, and perfume.

[0072] The term "pH-regulating” agent refers to acids or bases that can be used to adjust the pH of the finished product to the desired level, without affecting the stability of the solution. Examples of appropriate pH- regulating agents include, but are not limited to, acetic acid, lactic acid, citric acid, ethanolamine, formic acid, oxalic acid, potassium hydroxide, sodium hydroxide, triethanolamine, or their mixtures.

[0073] The term "gelling agent” refers to a compound that, when dissolved, suspended, or dispersed in a fluid (e.g., an aqueous fluid such as water or a buffer solution), forms a gelatinous semi-solid. Examples of gelling agents include but are not limited to hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl guar, methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, carbomer, alginate, gelatin, gums (such as Arabic gum, guar gum, gel Ian gum and Xanthan gum) vegetal lecithin, and poloxamers.

[0074] The term "thickening agent” or "thickener” or "viscosity agent "or "rheology modifier agent” which is herein used interchangeably refers to a material that increases its viscosity without substantially modifying its other properties. Examples of appropriate viscosity agents include, but are not limited to, cellulose or their derivatives such as hydroxypropyl methylcellulose, polyethylene glycol, microcrystalline cellulose, cetearyl alcohol, alginates, branched polysaccharides, fumed silica, xanthan gum, carbomer, gums, gelatines, and poly acrylates.

[0075] The terms "solvent” and "co-solvent” refer to substances capable of dissolving or dispersing another substance or ingredient; particularly the active ingredients and / or excipients of the present invention. Examples of solvents include, but are not limited to water, alcohols such as ethanol, isopropanol, 3-methoxy- 3-methyl-1-butanol; glycols such as butylene glycol, dipropylene glycol, dipropylene glycol methyl ether, and tripropylene glycol methyl ether; paraffin and isoparaffin waxes; silicone such as disiloxane and tetra siloxane; isopropyl myristate; (C12-C15) alkyl benzoate; and mixture thereof.

[0076] The term "preservative" refers to a material that prevents, reduces, or slows down microbial growth, providing that the stability of the solution is not affected. Examples of appropriate preservative agents include, but are not limited to, benzoic acid, butylparaben, ethylparaben, propylparaben, methylparaben, sorbic acid, potassium sorbate, sodium benzoate, phenoxyethanol, triclosan, or their mixtures.

[0077] The terms "filler" and "diluent" have the same meaning and are used interchangeably. They refer to any pharmaceutically acceptable excipient or carrier (material) that fill out the size of a composition, making it practical to produce and convenient for the consumer to use. Materials commonly used as filler include calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethyl cellulose, cellulose, cellulose products such as microcrystalline cellulose and its salts, dextrin derivatives, dextrin, dextrose, fructose, lactitol, lactose, starches or modified starches, magnesium carbonate, magnesium oxide, maltitol, maltodextrins, maltose, mannitol, sorbitol, starch, sucrose, sugar, xylitol, erythritol and mixtures thereof. In an embodiment, the composition of the invention is one wherein the pharmaceutically acceptable excipients or carriers comprises one or more filler. The term "emulsifying agent” or "emulsifier” which is herein used interchangeably refers to a material that reduces surface tension, promoting the formation of intimate mixtures of non-miscible liquids by altering the interfacial tension. Emulsifier stabilizes an emulsion by increasing its kinetic stability. Examples of appropriate emulsifier include, but are not limited to, glyceryl trioleate, glyceryl oleate, acetylated sucrose distearate, sorbitan trioleate, polyoxyethylene monostearate, glycerol monooleate, sucrose distearate, polyethylene glycol monostearate, octyl phenoxypoly (ethyleneoxy) ethanol, deacylerin penta-isostearate, sorbitan sesquioleate, hydroxylated lanolin, lecithin, lanolin, triglyceryl diisostearate, polyoxyethylene oleyl ether, calcium stearoyl-2-lactylate, sodium lauroyl lactylate, sodium stearoyl lactylate, cetearyl glucoside, methyl glucoside sesquistearate, sorbitan monopalmitate, methoxy polyethylene glycol-22 / dodecyl glycol copolymer, polyethylene glycol-45 / dodecyl glycol copolymer, polyethylene glycol 400 distearate and glyceryl stearate, candelil la / jojoba / rice bran polyglycery I-3 esters, cetyl phosphate, potassium cetyl phosphate, or their mixtures

[0078] The term "stabilizer” refers to a material which lowers the surface tension of a liquid and the interfacial tension between two liquids, allowing their easier spreading. Surfactants have a hydrophilic head that is attracted to water molecules and a hydrophobic tail that repels water and simultaneously attaches itself to oil and grease in dirt. These opposing forces loosen the dirt and suspend it in the water, having the ability to remove it from surfaces such as the human skin, textiles, and other solids, when surfactants are dissolved in water. Examples of appropriate surfactant agents include, but are not limited to, non-ionic, ionic (either anionic or cationic) or zwitterionic (or amphoteric wherein the head of the surfactant contains two oppositely charged groups) surfactants. Examples of anionic surfactants include, but are not limited to, those based on sulfate, sulfonate or carboxylate anions such as perfluorooctanoate (PFOA or PFO), alkyl benzene sulfonate, soaps, fatty acid salts, or alkyl sulfate salts such as perfluorooctanesulfonate (PFOS), sodium dodecyl sulfate (SDS), ammonium lauryl sulfate, sodium lauryl sulfate, sodium laureth sulfate, or sodium lauryl ether sulfate (SLES). Examples of cationic surfactants include, but are not limited to, those based on quaternary ammonium cations such as or alkyltrimethylammonium including cetyl trimethylammonium bromide (CTAB) a.k.a., or hexadecyl trimethyl ammonium bromide, cetylpyridinium chloride (CPC), polyethoxylated tallow amine (POEA), benzalkonium chloride (BAG), or benzethonium chloride (BZT). Examples of zwitterionic surfactants include, but are not limited to dodecyl betaine, cocamidopropyl betaine, or coco ampho glycinate. Examples of nonionic surfactants include, but are not limited to, alkyl poly (ethylene oxide), alkylphenol poly (ethylene oxide), copolymers of poly (ethylene oxide), poly (propylene oxide) (commercially called Poloxamers or Poloxamines), alkyl polyglucosides including octyl glucoside and decyl maltoside, fatty alcohols including cetyl alcohol and oleyl alcohol, cocamide MEA, cocamide DEA, or polysorbates including tween 20, tween 80, or dodecyl dimethylamine oxide. Typically, the amount of surfactant in the composition of the invention can be from 0.01 to 20% by weighty

[0079] The term "humectant” refers to a hygroscopic compound which attracts water molecules from the surrounding environment though either absorption or adsorption. Examples include but are not limited to, sodium hyaluronate, sodium hyaluronate, Glycerine, Liponic EG-1, Aquajuve, XIVIAC (xylitol), erythritol, Hyaluronic acid, Sorbitol, Collagen, and Aloe vera. The term "emollient” agent refers to a compound that softens and soothes the skin in order to correct dryness and scaling of the skin, lubricating the skin surface, encouraging skin water retention, and altering product textures. Examples include but are not limited to, sodium hyaluronate, saecare DC, massocare CO, She Butter oil, Dimethicone, Lauric Acid, and Capric Triglyceride.

[0080] The term "masking” refers to a compound capable of weaking or disappearing the feeling of odor and / or bad taste. Examples include but are not limited to trisodium citrate (E331), arginine, sorbitol, and triethylene glycol.

[0081] The term "opacifier" refers to substances capable of reducing the transparent and translucent appearance of a cosmetic composition by increasing its opacity. Examples include but are not limited to Euperlan PCO, Lamesoft TM, and Tinovis AD.

[0082] The terms "binding agent” and "binder” have the same meaning and are used interchangeably. They refer to any pharmaceutically acceptable excipient or carrier (material) having binding properties. Examples include but are not limited to polyvinylpyrrolidone K30, methylcellulose polymers, hydroxyethyl cellulose, hydroxypropyl cellulose, L-hydroxypropyl cellulose (low substituted), hydroxypropylmethyl cellulose (HPMC), sodium carboxymethyl cellulose, carboxymethylene, carboxymethyl hydroxyethyl cellulose and other cellulose derivatives, starches or modified starches and mixture thereof.

[0083] The term " sweetener” refers to a compound that imparts a sweet flavour and usually provides no or very low energy. Examples include but are not limited to Erylite, sucralose, Stevia, Fructose, and Neohesperidin.

[0084] The term "chelating” agent refers to a compound that binds at multiple points in a coordination complex to a solubilized (metal) ion. Examples of appropriate chelating agents include, but are not limited to phytic acid, malic acid, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), and alpha hydroxy acids

[0085] The term "flavouring” agent refers to a compound that supplements or strengthen the original flavour / taste of a substance. Examples of appropriate flavouring agents include, but are not limited to, sweetener, mint, strawberry, cherry, lemon, and liquorice, among others.

[0086] The term "fragrance” refers to a compound a combination of organic compounds that produces a distinct smell or odour. Examples of appropriate fragrances include, but are not limited to floral, fruity, woody, and musky, among others.

[0087] The term "perfume” refers to a liquid mixture of compounds used to emit a pleasant odour. The perfume is formed from fragrant essential oils derived from plants and spices and / or synthetic aromatic compounds. Examples of appropriate perfumes include, but are not limited to floral, fruity, woody, and musky, among others. In particular embodiments, the appropriate acceptable excipients or carriers may comprise one or more selected from the groups consisting of sodium lauryl sulfate, sodium laureth sulfate, methoxyisopropanol, and sodium citrate.

[0088] Another aspect of the invention is a process for the preparation of the compositions of the present invention as defined above. The compositions of the present invention can be prepared according to methods well known in the state of the art. The appropriate method and conditions can readily be determined by those skilled in the art according to the type of formulation being prepared.

[0089] Products

[0090] The second aspect of the present invention refers to a product comprising:

[0091] (i) an effective amount of a composition as defined in the first aspect of the invention; and

[0092] (ii) one or more appropriate acceptable excipients of carriers.

[0093] The term "effective amount” refers to the amount of the composition of the present invention which provide the alleged technical effect, which is the broad-spectrum biocidal activity as disclosed herein above. The effective amount of the composition that corresponds to the appropriate amount of the composition of the invention in the product, will of course be determined by the skilled in the art regarding the particular circumstances surrounding the case, including the particular pathogen and the condition to be treated or prevent, and the surrounding considerations.

[0094] In an embodiment, the product of the present invention comprises from 0.001 % to 50% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.001% to 7%w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.001% to 5%. w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.001 % to 4% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.001% to 3% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.01 % to 3% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.1% to 3% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.2% to 3% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 10% to 50% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 10% to 25% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 25% to 50% w / w of the composition of the present invention.

[0095] In an embodiment, the product of the present invention comprises from 0.1% to 2% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.1% to 1% w / w of the composition of the present invention. In an embodiment, the product of the present invention comprises from 0.1% to 0.5% w / w of the composition of the present invention, for example the product of the present invention comprises 0.2%, 0.3%, 0.4% w / w of the composition of the present invention. A product having a very high biocide activity with such low ingredient concentrations is only possible thanks to the synergic effect of the combination as disclosed in the present invention.

[0096] The composition of the present invention is effective against the most common pathogens (including bacteria, fungi, and yeast) that cause a higher incidence of disease in human and animals. This high effectivity and broad spectrum is achieved even of using a low effective amount of the composition such as from 0.01 to 0.3% w / w. In fact, the composition of the present invention is also effective against pathogens that have resistance to antibiotics (mainly because the spore formation capability). In this situation, the effective amount of the composition of the present invention can be from 0.1 to 5% w / w of the product. Nevertheless, these amount does not cause undesirable side effects (such as resistance or allergies) and it also has a very small impact on the environment and the ecosystem from which they are obtained or on living beings.

[0097] All the embodiments disclosed above for the composition of the first aspect of the invention also apply herein for the product of the second aspect of the invention.

[0098] The appropriate amount of the composition (I) as well as the excipients and / or carriers, and their amounts, can readily be determined by those skilled in the art according to the type of formulation being prepared and its application. Another aspect of the invention is a process for the preparation of the product of the present invention as defined above. The compositions of the present invention can be prepared according to methods well known in the state of the art. The appropriate method and conditions can readily be determined by those skilled in the art according to the type of formulation being prepared.

[0099] Examples of products of the second aspect of the invention include: pharmaceutical products, veterinary products, cosmetics, cleaning products (including laundry products), body hygiene products (including human as well as pet or livestock hygiene), perfumes, disinfectants for any use, food or feed products, food or feed additives, aquaculture, water treatment, and agricultural products (including phytosanitary products such as pesticides, fertilizers and biostimulants), adjuvants, and culture media.

[0100] Uses

[0101] It is also a part of the invention, the composition of the first aspect of the invention or the product of the second aspect of the invention for use in therapy. In an embodiment, the composition of the first aspect of the invention; or alternatively, the product of the second aspect of the invention for use in therapy as biocide; particularly, for use in the treatment or prevention of a bacterial, viral, fungal and yeast disease or condition. In other words, the composition of the first aspect of the invention; or alternatively, the product of the second aspect of the invention, is for use in the treatment or prevention of a human infection. Examples of bacterial, viral, fungal and yeast human disease or condition include, but are not limited to, VPH (Human Papilloma Virus), HBV (Hepatitis B), Coronavirus (including SARS-Cov-2), Herpes Virus, H7N9 (Influenza A), ECBO (Enterovirus Bovine), Rotavirus (viral Colitis), Vaccina Virus (smallpox), Polyoma Virus SV40, Bacteriophage for Lactobacillus, Poliovirus, Adenovirus, Norovirus (viral Colitis), Epstein-Barr, Polio virus type 1, LSc-2ab (Picornavirus), Adenovirus type 5, Strain Adenoid 75, ATCC VR-5, Murine norovirus, (Tobamovirus - ToBRFV, Strain S99 Berlin, Pseudomonas Aeruginosa, Escherichia Coll, Staphylococcus Aureus, Staphylococcus Epidermidis, Staphylococcus Hominis, Enterococcus Hirae, Burkholderia cepacia, Streptococcus mutans, Porphyromonas gingivalis, Pluribacter gergoviae, Fusobacterium nucleatum, Corynebacterium xerosis, Micrococcus spp, Lactobacillus acidophilus, Gardnerella vaginalis, Propionibacterium acnes, Legionella pneumophila, Proteus vulgaris, Salmonella (enteritis), Mycobacterium avium subsp. Paratuberculosis, Mycobacterium terrae, Listeria monocytogenes, Fungal Spores (Teliospores, Zoospores, Ascospores, Zygospores), Bacillus, Clostridia, Xylella Fastidiosa, Clostridium difficile, Erwinia amylovora, Xanthomonas arboricola pv. Pruni; Candida Albicans, Aspergillus Brasiliensis, Aspergillus Niger, Pityrosporum ovale, Campylobacter, Botrytis cinerea, Fusarium, Mildiu, Oidio, Phytophthora, Pythium, Fusarium oxysporum, Peronospora tabacina (tabaco), Phytophthora nicotinadiae (tabaco), Puccinia Horde!, Puccinia striiformis, Septoria tritici, Puccinia recondita, Puccinia graminis, Puccinia striiformis, Phytophthora cinnamon! Rands., Pythium spiculum, Pythium sterilum, Pythiaceae, Botryosphaeria corbicula, dotidiomycete fungus, ascomycete fungus, Order Xylariales, Biscogniauxia mediterranea, Agrobacterium tumefaciens, Pseudomonas savastanoi, and Agrobacterium vitis.

[0102] Therefore, the composition of the first aspect of the invention is a pharmaceutical composition and the appropriate acceptable excipients or carriers are pharmaceutically acceptable excipients or carriers; or alternatively, the product of the second aspect of the invention is a pharmaceutical product comprising: (!) a therapeutically effective amount of the composition; and one or more pharmaceutically acceptable excipients or carriers. The expression "therapeutically effective amount" as used herein, refers to the amount of active ingredients or composition containing them that, when administered, which is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of a human disease or condition that involves a bacterial, viral, fungal and yeast infection. The particular dose of the active ingredients or composition containing them administered according to this invention will of course be determined by the skilled in the art regarding the particular circumstances surrounding the case, including the particular condition being treated, and the similar considerations. And the term "pharmaceutically acceptable excipients or carriers” refers to that excipient or carrier suitable for use in the pharmaceutical technology for preparing compositions with medical use.

[0103] In an embodiment, the composition of the first aspect of the invention or the product of the second aspect of the invention is useful for the prevention and / or treatment of skin / scalp / hair disease or condition that involves a disorder of the sebaceous gland. In an embodiment, the composition of the first aspect of the invention or the product of the second aspect of the invention is useful for the treatment or prevention of acne, rosacea, and dermatitis. In an embodiment, the composition of the first aspect of the invention or the product of the second aspect of the invention is useful for the prevention and / or treatment of a disease or condition that involves an excessive or abnormal transpiration. Disease or conditions which involve an excessive or abnormal perspiration include hyperhidrosis, chromhidrosis and bromhidrosis.

[0104] It is also a part of the invention, the composition of the first aspect of the invention or the product of the second aspect of the invention for use in veterinary. In an embodiment, the composition of the first aspect of the invention; or alternatively, the product of the second aspect of the invention for use in veterinary as biocide; particularly, for use in the treatment or prevention of animal bacterial, viral, fungal and yeast disease or condition. In other words, the composition of the first aspect of the invention; or alternatively, the product of the second aspect of the invention is for use in the treatment or prevention of an animal infection. Examples of bacterial, viral, fungal and yeast animal disease or condition include, but are not limited to, the porcine reproductive and respiratory syndrome (PRRS), Influenza A virus subtype H3N8, and Brucellosis. Therefore, the composition of the first aspect of the invention is a veterinary composition and the appropriate acceptable excipients or carriers are pharmaceutically acceptable excipients or carriers; or alternatively, the product of the second aspect of the invention is a pharmaceutical product comprising: (i) a veterinary effective amount of the composition; and one or more veterinary acceptable excipients or carriers. The expression "veterinary effective amount" as used herein, refers to the amount of active ingredients or composition containing them that, when administered, which is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of an animal disease or condition that involves a bacterial, viral, fungal and yeast infection. The particular dose of the active ingredients or composition containing them administered according to this invention will of course be determined by the skilled in the art regarding the particular circumstances surrounding the case, including the particular condition being treated, and the similar considerations. And the term "veterinary acceptable excipients or carriers” refers to that excipient or carrier suitable for use in the veterinary technology for preparing compositions with veterinary use.

[0105] It is also a part of the invention, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in cosmetic. Therefore, the composition of the first aspect of the invention is a cosmetic composition and the appropriate acceptable excipients or carriers are cosmetically acceptable excipients or carriers; or alternatively, the product of the second aspect of the invention is a cosmetic product comprising: (i) a cosmetically effective amount of the composition; and one or more cosmetically acceptable excipients or carriers. The term used herein "cosmetically effective amount” refers to an amount enough to accomplish efficacies on cosmetic improvements in skin conditions described hereinabove. And the term "cosmetically acceptable” refers to that excipient or carrier suitable for use in contact with human skin without undue toxicity, incompatibility, instability, allergic response, among others for a non-medical use. The cosmetic composition of the present invention is designed to apply to the body to improve its appearance or to beautify, preserve, condition, cleanse, color or protect the skin, nails, or hair. Therefore, the above cosmetic compositions are adjectivally used for a non-medical application. In an embodiment, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in cosmetics is as a skin care agent. In an embodiment, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in cosmetics is as a skin care agent wherein the skin care comprises ameliorating at least one of the following symptoms: roughness, flakiness, dehydration, tightness, chapping, and lack of elasticity.

[0106] In an embodiment, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in cosmetics is as deodorant for reducing, minimizing, or eliminating the odour; particularly the body odour or clothes odour.

[0107] In an embodiment, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in cosmetics is as antioxidant and / or preventive agent. It is shown that the composition of the invention delays the degradation / deterioration of the components of a product that contains it, in turn extending the useful life of the final product.

[0108] It is also a part of the invention, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in agriculture. In an embodiment, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in agriculture is as phytosanitary agent; particularly, for use in the treatment or prevention of plant bacterial, viral, fungal and yeast disease or condition. In an embodiment, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in agriculture is as booster agent. The term "booster” refers to a compound capable of helping / upgrade the effectivity of other active ingredients, such as other phytosanitary agents, such as biocides (pesticides) or fertilizers. For the purpose of the invention, the composition of the present invention is capable of boost the inherent biocide activity of other biocides, as it is demonstrated in the experimental section. Therefore, it is useful as co-adjuvant agent for use in the treatment or prevention of plant bacterial, viral, fungal, nematode infection and yeast disease or condition. One embodiment provides the use of a composition according to the first aspect or product according to the second aspect, wherein the composition comprises a further active ingredient which is a phytosanitary agent. Another embodiment provides the use of a composition according to the first aspect or product according to the second aspect in agriculture, wherein the composition according to the first aspect or product according to the second aspect is used in combination with a further active ingredient which is a phytosanitary agent. In particular embodiments, the phytosanitary agent is selected from the group consisting of Calcium carbonate, potassium bicarbonate, methylcyclopropene, ABE-IT 56, Mancozeb, Azoxystrobin, Tebuconazole, Chlorothalonil, Propiconazole, Oxamyl, Metam sodium, 1 ,3-Dichloropropene, Fluensulfone, Phosthiazate, Oxytetracycline, Streptomycin, Copper oxychloride, Kasugamycin, Chloropicrin, Phosphorous acid, Phosphoric acid, methyl bromide, N-Trichloromethylthio-4-cyclohexene-1 ,2-dicarboximide, Fluor, Copper Hydroxide, a silver salt (such as silver nitrate, Silver sulfadiazine, Silver sulfate, Silver acetate, Silver oxide, Silver phosphate, or Silver thiosulfate), Silver nanoparticles, a Copper salt (such as Copper sulfate, Copper oxychloride, Copper hydroxide, or Dicopper trihydroxychloride), Cymoxanil, Metalaxyl, Folpet, and combinations thereof.

[0109] Examples of bacterial, viral, fungal, nematode infection and yeast plant disease or condition include, but are not limited to plants and fruit trees such as fire blight, bacterial spot of stone fruit trees and almond trees. Therefore, the composition of the first aspect of the invention is a phytosanitary composition and the appropriate acceptable excipients or carriers are agriculturally acceptable excipients or carriers; or alternatively, the product of the second aspect of the invention is a phytosanitary product comprising: (I) a phytosanitary effective amount of the composition; and one or more agriculturally acceptable excipients or carriers. The expression "phytosanitary effective amount" as used herein, refers to the amount of active ingredients or composition containing them that, when administered, which is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of a plant disease or condition that involves a plant bacterial, viral, fungal and yeast infection. The particular dose of the active ingredients or composition containing them administered according to this invention will of course be determined by the skilled in the art regarding the particular circumstances surrounding the case, including the particular condition being treated, and the similar considerations. And the term "agriculturally acceptable excipients or carriers” refers to that excipient or carrier suitable for use in agriculture for preparing compositions with phytosanity use. Examples of agriculturally acceptable excipients or carriers include, but not limited to, plant strengthens, nutrients, wetting agents, compounds that improve adherence, buffering compounds, stabilisers, antioxidants, osmotic protectors, and sunscreens.

[0110] In an embodiment, the composition of the first aspect of the invention is a dietary supplement and the appropriate acceptable excipients or carriers are edible acceptable excipients or carriers; or alternatively, the product of the second aspect of the invention is a dietary supplement comprising: (I) an effective amount of the composition; and one or more edible acceptable excipients or carriers. In terms of the present invention, the terms "dietary supplement”, "food / feed supplement” or "nutritional supplement” as used herein interchangeably refer to a composition or product intended to supplement the diet and provide nutrients, such as vitamins, minerals, fiber, fatty acids, or amino acids, which may be missing or may not be consumed in sufficient quantity in a person's or animal's diet. The term "edible” refers to compounds, compositions, complexes, salts, esters, excipients, and carriers that may be consumed by humans or animals without significant deleterious health consequences, it means that is suitable for consumption. For the purpose of the present invention the term "food / feed grade” and "edible” are equivalent and refers both the human and animal consumption. The particular dose of the active ingredients administered according to this invention will of course be determined by the skilled in the art regarding the particular circumstances surrounding the case. The term "edible acceptable excipients or carriers” refers to excipients or carriers suitable for use in the preparation of compositions or products which can be consumed by humans or animals without significant deleterious health consequences. In one embodiment, the dietary supplement according to the invention further comprises copper (in particular Copper Sulfate Pentahydrate CAS: 7758-99-8), Cimoxanil (CAS: 57966-95-7), or combinations thereof. It is also a part of the invention, the composition of the first aspect of the invention or the product of the second aspect of the invention for use in hygiene / disinfection / cleaning field.

[0111] In an embodiment, the composition of the first aspect of the invention; or alternatively, the product of the second aspect of the invention is useful as disinfectant. Therefore, the composition of the first aspect of the invention is a disinfectant composition and the appropriate acceptable excipients or carriers are acceptable excipients or carriers; or alternatively, the product of the second aspect of the invention is a disinfectant product comprising: (i) a disinfectant effective amount of the composition; and one or more acceptable excipients or carriers. The term "disinfectant” refers to a product which kills microorganisms on inanimate objects or spaces. Examples include hard surfaces, medical devices, surgical equipment, and air. The expression "disinfectant effective amount" as used herein, refers to the amount of active ingredients or composition containing them that, when administered, which is sufficient to kill bacteria, virus, fungi and yeast from inanimate surfaces or spaces. The particular dose of the active ingredients or composition containing them administered according to this invention will of course be determined by the skilled in the art regarding the particular circumstances. Suitable excipients or carriers for the disinfectant use can be anyone commonly used in antiseptic or disinfectant composition disclosed in the state of the art. For instance, the excipients or carriers can be selected from the group of dyes; flavours; solvents for instance glycols; diluents for instance water; surfactants for instance anionic surfactants; stabilizers; and rheologic modifiers. The composition of the present invention and the product containing it as disinfection include, but not limited to, disinfecting of utensils, equipment, facilities, air (environmental hygiene), surfaces and clothing (laundry); both at homecare services and professional care services. Examples include, disinfection of paediatric bottles and teats, facilities (toilet, kitchen, hotels, sanitary facilities-hospitals and adult or youth residences, sport centre, factories, laboratories, commercial centres, conference, and meetings rooms), vehicles (plain, bus, car, and motorcycle), and water treatment (wastewater treatment and potable water treatment). As it is mentioned above, the effectivity of the compositions of the invention is higher and prolonged in time than the effectivity shown for bleach.

[0112] One embodiment provides the use of a composition according to the first aspect or product according to the second aspect in cleaning / disinfecting, wherein the composition comprises a further active ingredient. Another embodiment provides the use of a composition according to the first aspect or product according to the second aspect in cleaning / disinfecting, wherein the composition according to the first aspect or product according to the second aspect is used in combination with a further active ingredient. In particular embodiments, the further active ingredient is selected from the group consisting of a further biocidal agent, a detergent (surfactant), and an enzyme. In particular examples the use is for cleaning and / or disinfecting and the product of the invention further comprises one or more surfactants and / or one or more enzymes. Nonlimiting examples of enzymes in the sense of the present invention are proteases, lipases, amylases, cellulases, mannanase, and pectinase. Proteases are included to break down protein residues such as blood, sweat and protein-rich food residues. They are especially useful in medical settings, laundries and deep cleaning of textiles. Lipases break down fats and oils. Lipases ensure effective removal of grease-based stains and are ideal for applications in the food industry and domestic cleaning of kitchen utensils. Amylases act on starches and carbohydrates, providing effective cleaning of food residues such as bread, pasta or sweetened beverages. Cellulases are included to treat fibrous residues and preserve fabric quality and are valuable in laundry detergents, helping to soften and maintain fiber durability. Mannanase and Pectinase address thickener and pectin residues, typical in processed foods and juices, being useful in food industries.

[0113] In certain embodiments it is provided the use of the composition of the first aspect of the invention; or alternatively, the product of the second aspect of the invention for cleaning and disinfecting. In one embodiment the use is for medical and surgical applications, e.g. for cleaning and disinfection of medical instruments, removing hard-to-reach organic residues. In another embodiment the use is for the industry, e.g. for cleaning / disinfecting food or feed processing plants. In this particular use the use of enzymes allows for effective removal of fats, carbohydrates and organic product residues accumulated on surfaces and machinery. In another embodiment the use is for laundry applications, e.g. for commercial and / or domestic laundries. In this particular application the product of the invention acts on food stains, blood, sweat and other organic and inorganic residues, offering deep cleaning and care of textiles. In another embodiment the use is for household cleaning, e.g. for cleaning surfaces such as carpets, kitchens and bathrooms, where organic residues such as grease and proteins are common. In another embodiment the use is for body care, including pet care, e.g. to remove specific stains and odours from urine, feces or vomit on surfaces and textiles.

[0114] It is also a part of the invention, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in the food / feed industry. In an embodiment, the composition of the first aspect of the invention is a food / feed additive and the appropriate acceptable excipients or carriers are edible acceptable excipients or carriers; or alternatively, the product of the second aspect of the invention is a food / feed additive comprising: (I) an effective amount of the composition; and one or more edible acceptable excipients or carriers. In terms of the present invention, the terms "food / feed additive”, refer to a composition or product intended to maintain or improve the safety, freshness, taste, texture, or appearance of food / feed, which is added. The particular dose of the active ingredients administered according to this invention will of course be determined by the skilled in the art regarding the particular circumstances surrounding the case. In an embodiment, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in the food / feed industry is selected from the group consisting of food / feed preservative, food / feed antioxidant, food / feed antiseptic, food / feed biocide, and technological adjuvant.

[0115] It is also a part of the invention, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in the scented / perfumery sector. In an embodiment, the composition of the first aspect of the invention is a scented composition and the appropriate acceptable excipients or carriers are; or alternatively, the product of the second aspect of the invention is a scented product comprising: (I) an effective amount of the composition; and one or more acceptable excipients or carriers. The term "appropriate acceptable” for the scented compositions and products of the present invention refers to that excipients or carriers suitable for use in perfumery, particularly in the cosmetic and freshener field for the preparation of scented articles with perfumery use. The term "scented” refers to any article that is intended for consumers and contains the composition or the article of the present invention. In an embodiment, the scented article of the invention is in form of an air freshener. Examples of scented products of the present invention include air fresheners. The term "air freshener” refers to a scented article, which comprises the composition of the present invention and including the aroma / fragrance / perfume, which is appropriate for putting in contact with the air of a space, being the space a closed internal space such as for example rooms and cupboards; or an open space.

[0116] It is also a part of the invention, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention in apiculture. Bees are essential insects for planet earth. Unfortunately, they are very delicate insects which suffer greatly from pesticides, air and water pollution, deforestation, and many other environmental hazards derived from human activity. As a result, bee population has dramatically decreased over the last decades, threatening life in the planet itself. The inventors have found that the composition of the invention may be successfully used in apiculture. For example, the product according to the invention may be applied by nebulization to varroa infected beehivese and successfully eliminated the parasite, without negatively affecting the bees. This is very surprising considering the fact that varroa mites have developed resistance to common biocides and, more importantly, that honeybees are so very sensitive to the biocides. Moreover, the bees were not repelled by the treatment, meaning that life and activity in the beehive continued as normal after the treatment. The composition of the invention, due to the its surprising efficacy and low toxicity achieved what hardly any other disinfectant has achieved in apiculture.

[0117] It is also a part of the invention, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention as a preservative in wood treatment, as an air disinfectant for both domestic and commercial use, either with electric devices or with the use of rechargeable or disposable batteries (single charge or with spare charges), as a bee hive disinfectant, as a bee feed supplement to eliminate pathogens such as, but not limited to, varroa, as a preservative and antioxidant in fuels, as a preservative in detergents and fabric softeners, as embalming and taxidermy liquids, as film preservatives (used for the preservation of films or coatings by controlling microbial deterioration or algal growth to protect the initial surface properties of materials or objects such as paints, plastics, sealants, wall adhesives, binders, papers or works of art), as protectors for fibres, leather, rubber and polymerised materials, as preservatives for building materials, as anti-mould products, as protectors for liquids used for working or cutting materials, or as products to control microbial spoilage of liquids used for working or cutting metals, glass or other materials.

[0118] It is also a part of the invention, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention for developing biocidal products. For this particular application the composition or product of the invention may be devoid of synthetic chemicals and, for example, may further comprise powdered egg or egg-derived compounds as matrices for developing biocidal products without synthetic chemicals.

[0119] It is also a part of the invention, the use of the composition of the first aspect of the invention or the use of the product of the second aspect of the invention for the production of antimicrobial and antifungal compounds. For this particular application the composition or product of the invention may further comprise yeast or yeast extract. Non-limiting yeast in the sense of this embodiment are Saccharomyces cerevisiae, Metschnikowia spp, Candida oleophila, Pichia spp, Rhodotorula spp, Kluyveromyces spp, Debaryomyces hansenii, and Hanseniaspora spp.

[0120] The compositions and the products of the present invention can be formulated in several forms according to the route of administration / application, the type of galenic formulation and the field of the art intended to be used.

[0121] In an embodiment, the compositions or products can be in a galenic form selected from the group consisting of liquid solutions, solids aerosols, non-aerosol sprays, sprays, shaving creams, powders, mousses, lotions, emulsions, gels, foams, powders, sticks, oils, ointments, pastes, creams, shampoos, shower gel, body washes, face washes, solid soaps, capsules, microcapsules, suspensions, liposomes, pellets, patch, and shower salts, wipes, tablets, capsules, and dry fog.

[0122] In an embodiment, the compositions or products are useful in the pharmaceutical, veterinary, cosmetic, and food / feed sectors and the route of administration is selected from the group consisting of oral, buccal, and topical.

[0123] Throughout the description and claims the word "comprise" and variations of the word, are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word "comprise” encompasses the case of "consisting of'. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples are provided by way of illustration, and they are not intended to be limiting of the present invention. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.

[0124] Examples

[0125] A. General consideration

[0126] Carvacrol, eucalyptol, terpinene-4-ol, thymol, and menthol were commercially available in food / feed grade by GUINAMA.

[0127] All strains of pathogenic microorganisms are available from ATCC (https: / / www.lgcstandards- atcc.org / en / About / About_ATCC / Who_We_Are.aspx). All these strains were used as examples of for performing the biocidal test of the compositions claimed in the present application. Other strains could also be used in their place to demonstrate the alleged biocide effect. Thus, the strains do not relate to the aim or focus of the invention.

[0128] B. Minimal Compositions of the present invention

[0129] 1. Minimum Inhibitory Concentration (MIC) test

[0130] The objective of the test described in the following points is to determine the minimum inhibitory concentration (MIC) of the compositions of the invention (compositions 1 and 2) and compare them to the MIC of each of the ingredients (carvacrol, eucalyptol, terpinene-4-ol) taken on their own or in binary combinations. An example was also included for a composition falling outside of the scope of the invention. The compositions are shown in table A. These compositions in table A were assayed against Pseudomonas aeruginosa microorganisms, and bacterial Biofilm.

[0131] Table A. Compositions assayed for MIC. Concentration of the ingredients in the compositions is expressed in % w / w

[0132] Preparation of compositions 1-3:

[0133] Step 1 . Each ingredient was weight separately;

[0134] Step 2. Carvacrol, Terpinen-4-ol and eucalyptol were mixed together at low stirring.

[0135] Step 3 Then, the resulting mixture was heated to a temperature ranged from 40-50°C

[0136] Step 4. When a dissolution was obtained, the temperature was allowed to fall.

[0137] Preparation of binary compositions:

[0138] Step 1 . Each ingredient was weight separately; Step 2. They were mixed together at low stirring

[0139] Step 3 Then, the resulting mixture was heated to a temperature ranged from 40-50°C

[0140] Step 4 When a dissolution was obtained, the temperature was allowed to fall.

[0141] Test description:

[0142] An initial inoculation of the organisms of interest was carried out on the surface. After the inoculation, an initial sampling was carried out before beginning the process of applying the products on the different surfaces. To do this, surface samples were taken with a sterile swab. To take surface samples, a moistened swab was used, the swab was removed from its sterile packaging and the tip was moistened by immersing it in a tube containing the diluent / neutral izer. The tip of the swab was pressed against the sides of the tube to remove excess diluent / neutralizer. The tips of the swabs were placed on the surfaces to be examined and an estimated area of about 100 cm2was rubbed in each of the areas, while the handle of each of the swabs was rotated between the thumb and forefinger. The sampling was be carried out in vertical and horizontal directions, 10 times in each direction. Swabs were returned to each tube with diluent / neutralizer. Tubes were closed so that the swabs remained moist until analysis.

[0143] After the initial sampling, the application of the products was started on different surfaces at different concentrations. No need to rinse with water once the product was applied.

[0144] After the application, samples were taken from the different surfaces after 1 minute. The samples were taken following the sampling method described in the initial sampling (T=0).

[0145] All samples taken once the sampling process was finished were kept refrigerated for preservation until analysis.

[0146] Once the sampling process was finished, we proceeded to carry out the tests of the microorganisms of interest in the Laboratory. The assays were carried out by plating in a selective medium, following at all times the following procedure.

[0147] Starting from the initial solution, for each microorganism to be inoculated, a first bank of dilutions is made in TSB medium to obtain the sample at different concentrations. In this way, through turbidity, we can make a first screening and determine between which concentrations our CMI will oscillate. In this assay, the following initial dilutions are prepared for each strain: 1% (0.01 g / mL), 0.1% (1mg / mL), 0.01% (0.1mg / ml), 0.001% (0.01mg / mL), 0.0001% (0.001 mg / mL).

[0148] All the tubes of the different concentrations are inoculated with each of the strains and incubated for 48h at 37°C. To ensure that the technique used works correctly and obtain reliable results, we will also put:

[0149] - Negative control sample: sample + TSB

[0150] - Negative process control (C-): medium TSB

[0151] - Positive control (C+): TSB medium + inoculum With the results obtained in the first screening, make another bank of dilutions in TSB medium, delimiting between the concentration in which no growth is observed and the one in which bacterial growth is observed, so in this way we can adjust the MIC that we are looking for. We inoculated each tube with the different strains. This time we will sow each tube on a plate to be able to have a count and also observe what the MIC will be on the plate. We put it to incubate 48h at 37° C. Once the incubation time has elapsed, read the tubes and plates and observe the minimum concentration in which there is no growth, this will be the Minimum Inhibitory Concentration.

[0152] Results obtained in tests against Pseudomonas aeruginosa (ATCC 15442) are shown in table B

[0153] Table B

[0154] Results obtained in tests against bacterial Biofilm (Listeria monocytogenes ATCC 35152, Aerobio 30° ATCC 25922, Clostridium sporogenes ATCC 19404, Candida albicans ATCC 26555 and Escherichia coli ATCC 10536 ) are shown in table C.

[0155] Table C

[0156] The above results shown in tables B and C show that the combination of Carvacrol, Terpinen- 4-ol and Eucalyptol has a MIC surprisingly lower that what would be expected from the MIC of each of the individual ingredients (see compositions 1 and 2). The combinations 1 and 2 containing Carvacrol, Terpinen- 4-ol and Eucalyptol also have a surprisingly lower MIC than binay combinations of these ingredients. Moreover, ternary combinations of Carvacrol, Terpinen- 4-ol and Eucalyptol outside the concentration range contemplated in the present invention have a significantly worst biocidal activity (higher MIC, see composition 3). Therefore, these results demonstrate that the minimal composition of the present invention has a synergistic effect between the 3 components that could not be expected.

[0157] 2. Biocidal efficacy

[0158] The objective of the test described herein was to determine the biocidal action of the composition 1 as defined in the previous example, used at 0.2% in water, against the microorganisms Pseudomonas aeruginosa (ATCC 15442) and HCoV- 299E (Human coronavirus 229E) ATCC VR-740.

[0159] Test description:

[0160] An initial inoculation of the organisms of interest was carried out on the surface as described in section 1.1. After the application, samples were taken from the different surfaces after 1 minute, 3 minutes and 7 minutes. The samples were taken following the sampling method described in the initial sampling (T=0).

[0161] All samples taken once the sampling process is finished were kept refrigerated for preservation until analysis. Once the sampling process was finished, we proceeded to carry out the tests of the microorganisms of interest in the Laboratory. The assays were carried out by plating in a selective medium, following UNE-EN 13697: 2015.

[0162] In view of the results obtained, it can be concluded that the composition, under the described conditions, has biocidal efficacy against Pseudomonas aeruginosa and Coronavirus starting after 1 minute of their application.

[0163] The above results show that the compositions of the invention achieve a very high biocide activity despite containing low active ingredient concentrations. Moreover, it is important that these products entail a low toxicity, such that they can be registered via a simplified authorisation procedure such as EU Regulation No 528 / 2012.

[0164] The simplified authorisation procedure (EU Regulation No 528 / 2012) aims to promote the use of biocidal products that are less harmful to the environment and to human and animal health. For a biocidal product to be subject to a simplified authorisation procedure it must meet all of the following conditions: ■ the biocidal product does not contain any substance of concern.

[0165] ■ the biocidal product does not contain nanomaterials

[0166] ■ the biocidal product is sufficiently effective

[0167] ■ the biocidal product does not require the use of personal protective equipment for its handling and its intended use

[0168] Having achieved a synergy between the different substances with a MIC of maximum 0.2% allows us to register a non-hazardous and non-toxic biocide product according to ECHA regulations (https: / / echa.europa.eu / es / regulations / biocidal-products-regulation / authorisation-of-biocidal- products / simplified-authorisation). This could not be achieved with any of the individual ingredients or combinations or binary combinations of the ingredients.

[0169] C. Booster effect

[0170] The following example evidences the booster effect provided by a composition according to the present invention on the biocidal activity of additional ingredients. In particular, the example shows that the composition 2 as defined in example 1 , used at 0.2% in water, significantly boosts the biocidal activity of Peppermint oil and tartaric acid against the microorganisms Pseudomonas aeruginosa (ATCC 15442) using the biocidal efficacy standard UNE-EN 13697:2024

[0171] 1. Minimum Inhibitory Concentration (MIC) of Peppermint oil and tartaric acid against Pseudomonas aeruginosa

[0172] The MIC for tartaric acid and peppermint oil against Pseudomonas aeruginosa (ATCC 15442) were each determined following the same procedure described in example B. The following table shows the obtained results:

[0173] 2. Biocidal efficacy

[0174] The objective of the test described in this work was to determine the biocidal action of composition 2 defined in the previous example, used at 0.2% in water plus 0.1 % of Pippermint oil in one case, and at 0.1 % of tartaric acid in another case, against Pseudomonas aeruginosa (ATCC 15442) to determine that the efficacy of pippermint oil and tartaric acid in combination with composition 2 is more effective than in comparison of the MIC with the active substances separately. The tests were carried out using the standard UNE-EN 13697:2024 under dirty conditions for 5 minutes.

[0175] Citation List

[0176] • cf. Halldor Thormar, Lipids and Essential Oils as Antimicrobial Agents, Wiley Ed, edition 2011, chapter 9- 11, pp. 203-262).

[0177] • European Standard protocol UNE-EN-13697:2015

[0178] • EU Regulation No 528 / 2012

[0179] • https: / / echa.europa.eu / es / regulations / biocidal-products-regulation / authorisation-of-biocidal- products / simplified-authorisation • European Standard protocol UNE-EN 13697:2024

Claims

Claims1. A composition comprising:(a) from 20% to 40% by weight of 5-lsopropil-2-metilfenol (carvacrol);(b) from 20% to 38% by weight of 1 ,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol);(c) from 21% to 38% by weight of 4-Methyl-1-(propan-2-yl)cyclohex-3-en-1-ol (terpinen-4-ol);(d) optionally, a further active ingredient selected from the group consisting of Tartaric acid, (9Z, 12E)- tetradeca-9, 12-dien-1 -yl acetate, Acetic acid, Arnica montana extract, Ascorbic acid, Bentonite, Carbon dioxide, Citronella, D-Fructose, Honey, Iron, Iron sulphate, Lavender oil, Linseed oil, Nitrogen, Oct-1 -en-3-ol, Peppermint oil, Potassium Sorbate, Propionic acid, Saccharomyces cerevisiae, Silicic acid or an aluminium, magnesium, or sodium salt thereof, Sodium acetate, Sodium benzoate, trisodium orthophosphate, lactic acid, citric acid, and combinations thereof; and(e) optionally, a further active ingredient selected from the group consisting of Calcium carbonate, potassium bicarbonate, methylcyclopropene, ABE-IT 56, Mancozeb, Azoxystrobin, Tebuconazole, Chlorothalonil, Propiconazole, Oxamyl, Metam sodium, 1 ,3-Dichloropropene, Fluensulfone, Phosthiazate, Oxytetracycline, Streptomycin, Copper oxychloride, Kasugamycin, Chloropicrin, Phosphorous acid, Phosphoric acid, methyl bromide, N-Trichloromethylthio-4-cyclohexene-1,2-dicarboximide, Fluor, Copper Hydroxide, a silver salt (such as silver nitrate, Silver sulfadiazine, Silver sulfate, Silver acetate, Silver oxide, Silver phosphate, or Silver thiosulfate), Silver nanoparticles, a Copper salt (such as Copper sulfate, Copper oxychloride, Copper hydroxide, or Dicopper trihydroxychloride), Cymoxanil, Metalaxyl, Folpet, Baculovirus, chabazite, cheese, concentrated apple juice, webbing clothes moths pheromone, Wolbachia pipientis strain wPip, vinegar, and combinations thereof; being the sum of ingredients up to 100% by weight.

2. The composition according to claim 1, comprising:(a) from 20% to 40% by weight of 5-lsopropil-2-metilfenol (carvacrol);(b) from 20% to 38% by weight of 1 ,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol);(c) from 21 % to 38% by weight of 4-Methyl-1-(propan-2-yl)cyclohex-3-en-1-ol (terpinen-4-ol); and(d) from 0.01 to 10% by weight of a further active ingredient selected from the group consisting of Tartaric acid, (9Z, 12E)-tetradeca-9, 12-dien-1-yl acetate, Acetic acid, Arnica montana extract, Ascorbic acid, Bentonite, Carbon dioxide, Citronella, D-Fructose, Honey, Iron, Iron sulphate, Lavender oil, Linseed oil, Nitrogen, Oct-1- en-3-ol, Peppermint oil, Potassium Sorbate, Propionic acid, Saccharomyces cerevisiae, Silicic acid or an aluminium, magnesium, or sodium salt thereof, Sodium acetate, Sodium benzoate, trisodium orthophosphate, acetic acid, and combinations thereof, or alternatively:(a) from 20% to 40% by weight of 5-lsopropil-2-metilfenol (carvacrol);(b) from 20% to 38% by weight of 1 ,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane (eucalyptol);(c) from 21 % to 38% by weight of 4-Methyl-1-(propan-2-yl)cyclohex-3-en-1-ol (terpinen-4-ol); and(d) from 0.01 to 10% by weight of a further active ingredient selected from the group consisting of Calcium carbonate, potassium bicarbonate, methylcyclopropene, ABE-IT 56, Mancozeb, Azoxystrobin, Tebuconazole, Chlorothalonil, Propiconazole, Oxamyl, Metam sodium, 1 ,3-Dichloropropene, Fluensulfone, Phosthiazate, Oxytetracycline, Streptomycin, Copper oxychloride, Kasugamycin, Chloropicrin, Phosphorous acid, Phosphoric acid, methyl bromide, N-Trichloromethylthio-4-cyclohexene-1 ,2-dicarboximide, Fluor, Copper Hydroxide, a silver salt (such as silver nitrate, Silver sulfadiazine, Silver sulfate, Silver acetate, Silver oxide, Silver phosphate, or Silver thiosulfate), Silver nanoparticles, a Copper salt (such as Copper sulfate, Copper oxychloride, Copper hydroxide, or Dicopper trihydroxychloride), Cymoxanil, Metalaxyl, Folpet, and combinations thereof; being the sum of ingredients up to 100% by weight.

3. The composition according to any one of claims 1-2, wherein the further active ingredient (d) is selected from the group consisting of Sodium benzoate, Sodium acetate, Peppermint oil, Citronella, acetic acid, Iron sulphate, Tartaric acid, Propionic acid, trisodium orthophosphate, Lavender oil, and combinations thereof.

4. The composition according to any one of claims 1-3, further comprising from 20% to 30% by weight of 5- Methyl-2-(propan-2-yl)phenol (thymol).

5. The composition according to any one of claims 1-4, further comprising 5-Methyl-2-(propan-2- yl)cyclohexan-1-ol (menthol).

6. The composition according to the preceding claim, further comprising one or more additional active ingredients selected from the group consisting of antibiotic, viricide, fungicide, yeasticide, bactericide, skin conditioner, and prebiotic, in particular, further comprising one or more additional active ingredients selected from the group consisting of organic acid containing compound; quaternary ammonium containing compound, such as quaternary ammonium silane salt; methyl n-methyl anthranilate, guaiacol, p-cresol, cinnamaldehyde, geraniol, citral, methyl dihydrojasmonate (Hedione), 3-(3-propan-2-ylphenyl)butanal (florhydral), cis-para- mentanol (Cyclohexane methanol, 4-(1 -methylethyl)-, cis-), delta-damascone, eugenol, p-cymene, alfa- pinene, beta-pinene, beta-caryophyllene, caryophylene oxyde, terpinene, and terpinolene, particularly, selected from the group consisting of hyaluronic acid, pyruvic acid, ferulic acid, benzalkonium chloride, dimethyl octadecyl[3-(trimethoxy silyl)propyl] ammonium chloride, methyl n-methyl anthranilate; guaiacol; p- cresol, cinnamaldehyde, geraniol, and citral.

7. The composition according to any of the claims 1-6, further comprising one or more appropriate acceptable excipients or carriers.

8. The composition according to any one of the preceding claims consisting of the ingredients as defined in any of the claims 1-7.

9. The composition according to any one of claims 1-8, wherein:(a) the concentration of carvacrol is from 20 to 34 % by weight;(b) the concentration of eucalyptol is from 20 to 34 % by weight;(c) the concentration of terpinen-4-ol is from 20 to 34 % by weight.

10. The composition according to any one of claims 1-9, wherein:(a) the concentration of carvacrol is from 30 to 34 % by weight;(b) the concentration of eucalyptol is from 30 to 34 % by weight;(c) the concentration of terpinen-4-ol is from 30 to 34 % by weight.

11. Product comprising:(I) 0.001% to 50% w / w of a composition as defined in any one of the preceding claims in relation to the total weight of the product, particularly from 0.01% to 2% of a composition as defined in any of the preceding claims in relation to the total weight of the product, more particularly particularly from 0.01% to 0.5% of a composition as defined in any of the preceding claims in relation to the total weight of the product; and (ii) one or more appropriate acceptable excipients of carriers.

12. The composition as defined in any one of claims 1-10; or alternatively, the product as defined in claim 11, which is selected from the group consisting of: a pharmaceutical composition or product comprising (I) a therapeutically effective amount of a composition as defined in any one of claims 1-10; and (ii) one or more pharmaceutically acceptable excipients or carriers; a veterinary composition or product comprising (I) a veterinary effective amount of a composition as defined in any one of claims 1-10; and (ii) one or more veterinary acceptable excipients or carriers; a cosmetic composition or product comprising (I) a cosmetically effective amount of a composition as defined in any one of claims 1-10; and (ii) one or more cosmetically acceptable excipients or carriers; a phytosanitary composition or product comprising (I) a phytosanitary effective amount of a composition as defined in any one of claims 1-10; and (ii) one or more agriculturally acceptable excipients or carriers; a disinfectant composition or product comprising (I) a disinfectant effective amount of a composition as defined in any one of claims 1-10; and (ii) one or more appropriate acceptable excipients or carriers; a dietary supplement composition or product comprising (I) an effective amount of a composition as defined in any one of claims 1-10; and (ii) one or more edible acceptable excipients or carriers;a food / feed additive composition or product comprising (i) an effective amount of a composition as defined in any one of claims 1-10; and (ii) one or more edible acceptable excipients or carriers; and a scented / perfumery composition or product comprising (i) appropriate amount of the composition as defined in any one of claims 1-10; and (ii) one or more appropriate excipients or carriers.

13. A method for preparing a product according to any one of claims 11-12, said method comprising mixing a composition as defined in any one of claims 1-10 with one or more appropriate acceptable excipients of carriers.

14. The product according to any one of claims 11-12, which is: a pharmaceutical product for use in therapy or a veterinary product for use in veterinary, particularly, for use as biocide, particularly, for use in the treatment or prevention of bacterial, viral, fungal, nematode infection or yeast disease or condition, particularly, for use in the treatment or prevention of a bacterial, viral, fungal, yeast disease or condition caused by a pathogen selected from the group consisting of VPH (Human Papilloma virus), HBV (Hepatitis B), Coronavirus, Herpes Virus, H7N9 (Influenza A), ECBO (Enterovirus Bovine), Rotavirus (viral Colitis), Vaccina Virus (smallpox), Polyoma Virus SV40, Bacteriophage for Lactobacillus, Poliovirus, Adenovirus, Norovirus (viral Colitis), Epstein-Barr, Polio virus type 1, LSc-2ab (Picornavirus), Adenovirus type 5, Strain Adenoid 75, ATCC VR-5, Murine norovirus, Strain S99 Berlin, Pseudomonas Aeruginosa, Escherichia Coll, Staphylococcus Aureus, Staphylococcus Epidermidis, Staphylococcus Hominis, Enterococcus Hirae, Burkholderia cepacia, Streptococcus mutans, Porphyromonas gingivalis, Fusobacterium nucleatum, Mycobacterium avium subsp. Paratuberculosis, Mycobacterium terrae, Pluribacter gergoviae Corynebacterium xerosis, Micrococcus spp, Lactobacillus acidophilus, Gardnerella vaginalis, Propionibacterium acnes, Legionella pneumophila, Proteus vulgaris, Salmonella (enteritis), Listeria monocytogenes, Fungal Spores (Teliospores, Zoospores, Ascospores, Zygospores), Bacillus, Clostridia, Xylella Fastidiosa, Clostridium difficile, Acinetobacter baumanii Erwinia amylovora, Xanthomonas arboricola pv. Pruni; Candida Albicans, Aspergillus Brasiliensis, Aspergillus Niger, Pityrosporum ovale, Campylobacter, Botrytis cinerea, Fusarium, Mildiu, Oidio, Phytophthora, Pythium, Fusarium oxysporum, Peronospora tabacina (tabaco), Phytophthora nicotinadiae (tabaco), Puccinia Horde!, Puccinia striiformis, Septoria tritici, Puccinia recondita, Puccinia graminis, Puccinia striiformis, Phytophthora cinnamon! Rands., Pythium spiculum, Pythium sterilum, Pythiaceae, Botryosphaeria corticola, dotidiomycete fungus, ascomycete fungus, Order Xylariales, Biscogniauxia mediterranea, Agrobacterium tumefaciens, Pseudomonas savastanoi, and Agrobacterium vitis, or alternatively a cosmetic product in cosmetics, particularly, as skin care agent; more particularly, wherein the skin care comprises ameliorating at least one of the following symptoms: roughness, flakiness, dehydration, tightness, chapping, and lack of elasticity, particularly, as deodorant, and particularly, as antioxidant and / or preservative agent; or alternativelya phytosanitary product as phytosanitary biocide or booster agent, particularly, for the treatment or prevention of a bacterial, viral, fungal, or yeast plant disease or condition; more particularly, for a plant disease or condition, more particularly, for a plant and fruit trees caused by a pathogen selected from the group consisting of fire blight, bacterial spot of stone fruit trees and almond trees.

15. Use of the product according to any one of claims 11-12, which is: a disinfectant product as disinfectant agent; particularly, as disinfectant of solid surfaces, spaces, and water; or alternatively, a food / feed additive product as food / feed preservative, food / feed antioxidant, food / feed antiseptic and food / feed biocide, and technological adjuvant.

Images